Sugi Predict

Sugi Predict / Targets / BIRC5

BIRC5

Baculoviral IAP repeat-containing protein 5 · O15392 · BIRC5 on Sugi Atlas →

5,699 patent compounds predicted against BIRC5, 3,612 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2069672 SCHEMBL2069672 1.00 20/20
SCHEMBL2070068 SCHEMBL2070068 1.00 20/20
SCHEMBL2070256 SCHEMBL2070256 1.00 20/20
SCHEMBL2070303 SCHEMBL2070303 1.00 20/20
SCHEMBL2070366 SCHEMBL2070366 1.00 20/20
SCHEMBL2070429 SCHEMBL2070429 1.00 20/20
SCHEMBL2070437 SCHEMBL2070437 1.00 20/20
SCHEMBL2070581 SCHEMBL2070581 1.00 20/20
SCHEMBL2071287 SCHEMBL2071287 1.00 20/20
SCHEMBL2071469 SCHEMBL2071469 1.00 20/20
SCHEMBL2072235 SCHEMBL2072235 1.00 20/20
SCHEMBL2072264 SCHEMBL2072264 1.00 20/20
SCHEMBL2072346 SCHEMBL2072346 1.00 20/20
SCHEMBL2070300 SCHEMBL2070300 0.94 20/20
SCHEMBL2070645 SCHEMBL2070645 0.91 20/20
SCHEMBL2071297 SCHEMBL2071297 0.87 20/20
SCHEMBL2070669 SCHEMBL2070669 0.87 20/20
SCHEMBL2071905 SCHEMBL2071905 0.87 20/20
SCHEMBL2072009 SCHEMBL2072009 0.87 20/20
SCHEMBL2069235 SCHEMBL2069235 0.86 20/20

Clinical trials — most relevant to BIRC5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Enhancing Effect on Tumour Apoptosis With the Use of Pentoxifylline in Patients With Hodgkin Lymphoma PHASE4UNKNOWN
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC) PHASE1/PHASE2WITHDRAWN
XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) PHASE1/PHASE2COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) PHASE1/PHASE2COMPLETED
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer PHASE2COMPLETED
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma PHASE1ACTIVE_NOT_RECRUITING
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma PHASE1COMPLETED
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma PHASE1COMPLETED
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma PHASE1ACTIVE_NOT_RECRUITING
Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas PHASE1COMPLETED
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma PHASE1ACTIVE_NOT_RECRUITING
A Phase I, Open-Labeled, Single-Arm, Dose Escalation, Clinical and Pharmacology Study of Dichloroacetate (DCA) in Patients With Recurrent and/or Metastatic Solid Tumours PHASE1COMPLETED
In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects PHASE1COMPLETED
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer PHASE1UNKNOWN
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma PHASE1WITHDRAWN
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage nanCOMPLETED
Dietary Intervention With High Phenolic EVOO in CLL nanCOMPLETED
MSUS Versus Serum Survivin and Lubricin Levels in Evaluation of Disease Activity in JIA nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN
Molecular Mechanism of Nasopharyngeal Carcinoma nanUNKNOWN
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases nanUNKNOWN
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
The Effect of TRA-8 on Ovarian Cancer Tissue nanCOMPLETED
Circulating Markers for Ischemic Heart Disease nanRECRUITING
Role of Vaspin in Pathophysiology of Pre-eclampsia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a BIRC5 binder may also engage these)

ProteinNameSimilarity
Q5RAH9 — 1.000 Q5RAH9 →
Q6I6F4 — 0.999 Q6I6F4 →
Q9GLN5 — 0.999 Q9GLN5 →
Q8I009 — 0.997 Q8I009 →
Q6J1J1 — 0.996 Q6J1J1 →
E3SCZ8 — 0.988 E3SCZ8 →
O70201 — 0.975 O70201 →
Q9JHY7 — 0.975 Q9JHY7 →
P26450 — 0.929 P26450 →
PIK3R1 Phosphatidylinositol 3-kinase regulatory subunit alpha 0.929 landscape →
HELZ Probable helicase with zinc finger domain 0.928 landscape →
Q6DFV5 — 0.927 Q6DFV5 →
HAT1 Histone acetyltransferase type B catalytic subunit 0.927 landscape →
Q9CZW5 — 0.927 Q9CZW5 →
Q6TUI4 — 0.927 Q6TUI4 →
Q5R5F8 — 0.927 Q5R5F8 →
Q8R418 — 0.927 Q8R418 →
Q923S8 — 0.926 Q923S8 →
Q63787 — 0.926 Q63787 →
Q5ZIA0 — 0.926 Q5ZIA0 →
Q75Q39 — 0.926 Q75Q39 →
USP47 Ubiquitin carboxyl-terminal hydrolase 47 0.926 landscape →
Q4R4U1 — 0.925 Q4R4U1 →
A0MQH0 — 0.925 A0MQH0 →
E1C1R4 — 0.925 E1C1R4 →
Q9NVE7 — 0.925 Q9NVE7 →
A0A8J1LLF7 — 0.925 A0A8J1LLF7 →
P23727 — 0.924 P23727 →
A0A974H8H3 — 0.924 A0A974H8H3 →
B3DLA6 — 0.924 B3DLA6 →